Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Human Respiratory Syncytial Virus 100%
• Lower Respiratory Tract Infection 100%
• Adverse Event 16%
• Immunogenicity 8%
• Antivirus Agent 8%
• Disease Course 8%
• Respiratory Tract Inflammation 8%
• Antiviral Activity 8%
• Nanobody 8%
• Antiviral Drug 8%
• Pharmacokinetics 8%
• Treatment Group 8%

Keyphrases

• Control Phase 100%
• Severe Lower Respiratory Tract Infection 20%
• Respiratory Tract Inflammation 10%
• Safety Activities 10%
• Anti-drug Antibodies 10%
• Oral Feeding 10%